In Brief This Week: Intrexon, Trans Ova Genetics; Bluebird Bio, Pregenen; Bio-Techne, Novus Biologicals; Genesis Genetics; Enzo Biochem; CeGaT, N-of-One | GenomeWeb

NEW YORK (GenomeWeb) – Intrexon has entered into a definitive agreement to buy bovine genetics firm Trans Ova Genetics for up to $110 million. Shareholders will receive $60 million in upfront cash, $30 million in Intrexon stock, and up to $20 million in deferred payments. Trans Ova will become a wholly owned subsidiary of Intrexon upon completion of the transaction, which is expected in the third quarter, and will be led by David Faber, currently Trans Ova's president, and his management team.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.